CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver...
CymaBay Therapeutics Inc. (CBAY)
Last cymabay therapeutics inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cymabay.com
Company Research
Source: GlobeNewswire
52-week analysis highlights the potential for seladelpar to offer patients improved efficacy and better tolerability than existing second line treatmentThird consecutive year data from the development of seladelpar in PBC will be highlighted in a late-breaking presentation at The Liver Meeting® NEWARK, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced that two late-breaking presentations describing new long-term data from its ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC) will be featured on November 12, 2018 during The Liver Meeting® hosted by the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA (November 9-13, 2018). Seladelpar is an orally administered, potent and selective peroxisome proliferator-activated receptor delta (PPARd) agonist currently in development for PBC and nonalcoholic steatohepatitis (NASH). The first presentation, abstract LB-3, titled
Show less
Read more
Impact Snapshot
Event Time:
CBAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CBAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CBAY alerts
High impacting CymaBay Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CBAY
News
- Gilead posts quarterly loss, revenue rises 5% [Reuters]Reuters
- Gilead posts quarterly loss, revenue rises 5% [Yahoo! Finance]Yahoo! Finance
- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain [Yahoo! Finance]Yahoo! Finance
CBAY
Earnings
- 11/7/23 - Miss
CBAY
Sec Filings
- 3/22/24 - Form 4
- 3/22/24 - Form 4
- 3/22/24 - Form 4
- CBAY's page on the SEC website